Logo

Astellas and Seattle Genetics' PADCEV (enfortumab vedotin-ejfv) Receives the US FDA's Approval for Locally Advanced or Metastatic Urothelial Cancer in Adults

Share this

Astellas and Seattle Genetics' PADCEV (enfortumab vedotin-ejfv) Receives the US FDA's Approval for Locally Advanced or Metastatic Urothelial Cancer in Adults

  • The PADCEV was evaluated in P-II EV-201 Trial to evaluate 125 patients locally advanced or metastatic urothelial cancer who received who received prior treatment with a PD-1 or PD-L1 inhibitor and a Pt-based CT
  • The study resulted in ORR 44%- CR 12% leading no cancer detection at time of assessment- PR 32% meaning a decrease in tumor size or extent of cancer in the body- DoR 7.6 mos.
  • PADCEV is a novel ADC directed against Nectin-4 a protein located on the surface of cells and highly expressed in bladder cancer and is currently evaluated in P-III EV-301Trial

Click here to read full press release/ article | Ref: Astellas | Image: Astellas


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions